Angiotensin-converting enzyme 2 activity in patients with chronic kidney disease

Nephrology Dialysis Transplantation

Volumn 28, Issue 9, 2013, Pages 2287-2294

  Roberts, Matthew A ^a,b   Velkoska, Elena ^b   Ierino, Francesco L ^a,b   Burrell, Louise M ^a,b  

^a AUSTIN HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Angiotensin converting enzyme 2; Cardiovascular disease; Chronic dialysis; Chronic kidney disease; End stage kidney disease

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME BLOOD LEVEL; FEMALE; FLUORESCENCE ANALYSIS; GRAFT RECIPIENT; HEMODIALYSIS PATIENT; HUMAN; KIDNEY GRAFT; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN-CONVERTING ENZYME 2; CARDIOVASCULAR DISEASE; CHRONIC DIALYSIS; CHRONIC KIDNEY DISEASE; END-STAGE KIDNEY DISEASE;

AGED; BIOLOGICAL MARKERS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; PROGNOSIS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84880968521     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft038     Document Type: Article

References (31)

1. Grace B, Excell L, Dent H et al. New patients, in ANZDATA Registry Report 2010. In: Mcdonald S, Excell L, Livingston B (eds). Australia and New Zealand Dialysis and Transplant Registry. South Australia: Adelaide, 2010, pp. 2-1-2-12
2. Roberts MA, Polkinghorne KR, McDonald SP et al. Secular trends in cardiovascular mortality rates of patients receiving dialysis compared with the general population. Am J Kidney Dis 2011; 58: 64-72
3. Roberts MA, Hare DL, Ratnaike S et al. Cardiovascular biomarkers in CKD: pathophysiology and implications for clinical management of cardiac disease. Am J Kidney Dis 2006; 48: 341-360
4. Velez JC. The importance of the intrarenal renin-angiotensin system. Nat Clin Pract Nephrol 2009; 5: 89-100
5. Parving HH, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878
6. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
7. Donoghue M, Hsieh F, Baronas E et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87: E1-9
8. Santos RA, Simoese Silva AC, Maric C et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 2003; 100: 8258-8263
9. Burrell LM, Risvanis J, Kubota E et al. Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J 2005; 26: 369-375
10. Reich HN, Oudit GY, Penninger JM et al. Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. Kidney Int 2008; 74: 1610-1616
11. Mizuiri S, Hemmi H, Arita M et al. Expression of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls. Am J Kidney Dis 2008; 51: 613-623
12. Tikellis C, Bialkowski K, Pete J et al. ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes. Diabetes 2008; 57: 1018-1025
13. Burrell LM, Johnston CI, Tikellis C et al. ACE2, a new regulator of the renin-angiotensin system. Trends Endocrinol Metab 2004; 15: 166-169
14. Crackower MA, Sarao R, Oudit GY et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002; 417: 822-828
15. Ye M, Wysocki J, William J et al. Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol 2006; 17: 3067-3075
16. Soler MJ, Wysocki J, Ye M et al. ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice. Kidney Int 2007; 72: 614-623
17. Oudit GY, Herzenberg AM, Kassiri Z et al. Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis. Am J Pathol 2006; 168: 1808-1820
18. Lambert DW, Yarski M, Warner FJ et al. Tumor necrosis factoralpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem 2005; 280: 30113-30119
19. Lew RA, Warner FJ, Hanchapola I et al. Angiotensin-converting enzyme 2 catalytic activity in human plasma is masked by an endogenous inhibitor. Exp Physiol 2008; 93: 685-693
20. Chong CP, Lim WK, Velkoska E et al. N-terminal pro-brain natriuretic peptide and angiotensin-converting enzyme-2 levels and their association with postoperative cardiac complications after emergency orthopedic surgery. Am J Cardiol 2012; 109: 1365-1373
21. Soro-Paavonen A, Gordin D, Forsblom C et al. Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications. J Hypertens 2012; 30: 375-383
22. Roberts MA, Hare DL, Macmillan N et al. Serial increased cardiac troponin T predicts mortality in asymptomatic patients treated with chronic haemodialysis. Ann Clin Biochem 2009; 46: 291-295
23. Roberts MA, Macmillan N, Hare DL et al. Cardiac troponin levels in asymptomatic patients on the renal transplant waiting list. Nephrology 2006; 11: 471-476
24. Roberts MA, Srivastava PM, Macmillan N et al. B-type natriuretic peptides strongly predict mortality in patients who are treated with long-term dialysis. Clin J Am Soc Nephrol 2008; 3: 1057-1065
25. Poge U, Gerhardt T, Palmedo H et al. MDRD equations for estimation of GFR in renal transplant recipients. Am J Transplant 2005; 5: 1306-1311
26. Vittinghoff E, Glidden D, Shiboski S et al. Chapter 4.7.5.: interpretation of results for log-transformed variables. In: Regression Methods in Biostatistics Linear, Logistic, Survival and Repeated Measures Models. New York: Springer, 2005, pp. 125-127
27. Velkoska E, Dean RG, Burchill L et al. Reduction in renal ACE2 expression in subtotal nephrectomy in rats is ameliorated with ACE inhibition. Clin Sci 2010; 118: 269-279
28. Velkoska E, Dean RG, Griggs K et al. Angiotensin-(1-7) infusion is associated with increased blood pressure and adverse cardiac remodelling in rats with subtotal nephrectomy. Clin Sci 2011; 120: 335-345
29. Burrell LM, Burchill L, Dean RG et al. Chronic kidney disease: cardiac and renal angiotensin converting enzyme (ACE) 2 expression in rats after subtotal nephrectomy and the effect of ACE inhibition. Exp Physiol 2012; 97: 477-485
30. Madsen LH, Ladefoged S, Corell P et al. N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis. Kidney Int 2007; 71: 548-554
31. Epelman S, Shrestha K, Troughton RW et al. Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes. J Card Fail 2009; 15: 565-571